Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05444894 · ClinicalTrials.gov registry record · Phase 1
EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)
A Phase 1 study of Hemoglobinopathies and Transfusion-dependent Beta-Thalassemia, sponsored by Editas Medicine.
- Active
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 8
- Study locations
NCT05444894: Active Phase 1 study of Hemoglobinopathies and Transfusion-dependent Beta-Thalassemia, sponsored by Editas Medicine.
NCT05444894 is a Phase 1 study of Hemoglobinopathies and Transfusion-dependent Beta-Thalassemia that is active but no longer recruiting, run by Editas Medicine. The registered enrollment target is 9 participants, below the 1,803-participant average among 17 other Hemoglobinopathies trials with a reported enrollment target (100% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05444894, a Phase 1 study of Hemoglobinopathies and Transfusion-dependent Beta-Thalassemia, is active but no longer recruiting, sponsored by Editas Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of treatment with EDIT-301 in adult participants with Transfusion Dependent beta Thalassemia
Conditions Studied
Interventions
- GENETIC EDIT-301
Study Locations (8)
New York
- Columbia University Medical Center - Department of Pediatrics - New York
- Columbia University Medical Center - New York
California
- University of California San Francisco - Oakland
Minnesota
- University of Minnesota - Minneapolis
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Tennessee
- Tristar Medical Group Children's Specialists/Sarah Cannon Center for Blood Cancers - Nashville
Ontario
- Princess Margaret Cancer Centre-University Health Network - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-04-29 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What the registry record for NCT05444894 still lists
NCT05444894 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,803-participant average among 17 other Hemoglobinopathies trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Hemoglobinopathies appearing as the primary indexed condition, and to 1 intervention - of which EDIT-301 is the first listed.
NCT05444894 lists 8 locations in 7 states (New York, California, Minnesota).
Frequently Asked Questions
What is clinical trial NCT05444894 about?
NCT05444894 is a clinical study titled "EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)". The purpose of this study is to evaluate the safety, tolerability, and efficacy of treatment with EDIT-301 in adult participants with Transfusion Dependent beta Thalassemia
What is the current status of trial NCT05444894?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2022-04-29. Estimated completion is 2025-12.
What conditions does trial NCT05444894 study?
This clinical trial studies the following conditions: Hemoglobinopathies, Transfusion-dependent Beta-Thalassemia, Thalassemia Major, Thalassemia Intermedia.
What interventions are being tested in trial NCT05444894?
The interventions under investigation include: EDIT-301 (GENETIC).
Who is sponsoring clinical trial NCT05444894?
This trial is sponsored by Editas Medicine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05444894 being conducted?
This trial has 8 study locations across California, Minnesota, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemoglobinopathies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05444894's enrollment target sits among peer trials
9 15th of 17 higher than 3 of 17 other Hemoglobinopathies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemoglobinopathies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
RECRUITING · Phase 1
-
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
RECRUITING · Phase 1
-
A Blood Stem Cell Transplant for Sickle Cell Disease
ACTIVE NOT RECRUITING · Phase 1
-
A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)
ACTIVE NOT RECRUITING · Phase 1
-
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
COMPLETED · Phase 1
-
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI